Changes in FDG uptake after subsequent cycles of neoadjuvant therapy can predict long-term patient survival. Researchers from the Technical University of Munich reported these findings at the Society of Nuclear Medicine meeting in June.
Changes in FDG uptake after subsequent cycles of neoadjuvant therapy can predict long-term patient survival. Researchers from the Technical University of Munich reported these findings at the Society of Nuclear Medicine meeting in June.
Dr. Stefanie Sassen and colleagues enrolled 33 patients who underwent FDG-PET imaging of the abdomen and pelvis before and after carboplatin-based chemotherapy. Patients went on to debulking surgery after chemo and were monitored for three years.
The researchers observed a significant correlation between FDG-PET uptake changes and patient survival after the first and third cycles of therapy. Overall survival of patients classified as responders and nonresponders to FDG-PET was 38.9 months and 19.7 months, respectively.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study: AI Model Significantly Enhances CTA Workflow Efficiency and Detection for Cerebral Aneurysm
October 18th 2024Adjunctive use of deep learning reportedly led to a 37 percent reduction of interpretation time for cerebral aneurysm assessment on computed tomography angiography (CTA) and greater than a 90 percent reduction in post-processing time.